Apotex Health Corp experienced three significant insider trading transactions on September 18, 2026, totaling 850 million CAD in sales. Major shareholders, including SK Artemis Holdings II and API Investment LP, alongside director Allan Grant Oberman, divested substantial equity positions. These disposals occurred amidst a 10.3% stock price increase over the preceding ninety-day period.